stockportfolio.pro
Ligand Pharmaceuticals Incorporated P/E Ratio 2009–2025
Ligand Pharmaceuticals Incorporated (LGND) annual price-to-earnings ratio by fiscal year, computed from SEC filings. Compound growth +4.6%/yr over 16 years.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 30.84 | — |
| FY 2024 | — | — |
| FY 2023 | 24.29 | — |
| FY 2022 | — | — |
| FY 2021 | 29.11 | — |
| FY 2020 | — | — |
| FY 2019 | 2.04 | -85.6% |
| FY 2018 | 14.20 | -91.2% |
| FY 2017 | 161.17 | — |
| FY 2016 | — | — |
| FY 2015 | 6.25 | -89.5% |
| FY 2014 | 59.28 | -0.6% |
| FY 2013 | 59.66 | — |
| FY 2012 | — | — |
| FY 2011 | 15.11 | — |
| FY 2010 | — | — |
| FY 2009 | — | — |
Source: Ligand Pharmaceuticals Incorporated SEC filings — fiscal-year-end price ÷ diluted EPS. Refreshed nightly.
See the full picture for Ligand Pharmaceuticals Incorporated
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeLigand Pharmaceuticals Incorporated — frequently asked questions
What is Ligand Pharmaceuticals Incorporated's price-to-earnings ratio?
Ligand Pharmaceuticals Incorporated (LGND) reported price-to-earnings ratio of 30.84 for fiscal year 2025, per its SEC filings.
How has Ligand Pharmaceuticals Incorporated's price-to-earnings ratio changed over time?
Between fiscal 2009 and 2025, LGND's price-to-earnings ratio grew at roughly 4.6% per year (compound annual rate), from 15.11 to 30.84.
Where does this data come from?
Figures are computed from Ligand Pharmaceuticals Incorporated's official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.